Patents by Inventor Mohammad A. Heidaran
Mohammad A. Heidaran has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240011053Abstract: Mental diseases include a heterogenous array of diseases that affect brain function. Evidence suggests that some of more serious conditions that lead to suicide may have some genetic and epigenetic determinants. Single Nucleotide Polymorphism (SNPs) have been identified that correlate with a variety of mental conditions and diseases. In this patent application we describe a method by which subjects with life threatening mental health disease can be identified using Single Nucleotide Polymorphism (SNP) analysis and such associated SNPs is corrected using in vivo genome editing technologies.Type: ApplicationFiled: June 13, 2022Publication date: January 11, 2024Inventor: Mohammad A Heidaran
-
Publication number: 20230090316Abstract: The present invention provides methods of treating one or more complications of premature birth suffered by premature infants, comprising administering to the premature infant umbilical cord blood stem cells and, optionally, placental stem cells. The present invention also provides methods of combining and administering, and compositions comprising, umbilical cord blood stem cells, particularly autologous cord blood cells, and placental stem cells for the treatment of premature infants.Type: ApplicationFiled: November 21, 2022Publication date: March 23, 2023Applicant: Celularity Inc.Inventors: Mohammad A. HEIDARAN, Robert J. HARIRI, Kristine Erickson Johnson
-
Publication number: 20220259563Abstract: Provided herein are methods of producing natural killer cells using a two-step expansion and differentiation method. Also provided herein are methods of suppressing tumor cell proliferation, of treating individuals having cancer or a viral infection, comprising administering the NK cells produced by the method to an individual having the cancer or viral infection.Type: ApplicationFiled: April 29, 2022Publication date: August 18, 2022Applicant: Celularity Inc.Inventors: Robert J. HARIRI, Mohammad A. Heidaran, Stephen Jasko, Lin Kang, Eric Law, Ajai Pal, Bhavani Stout, Vanessa Voskinarian-Berse, Andrew Zeitlin, Xiaokui Zhang
-
Publication number: 20210121452Abstract: Provided herein are methods of suppressing tumor cell proliferation, of treating individuals having cancer or a viral infection, comprising contacting the tumor cells, or administering to the individual, placental perfusate, placental perfusate cells, or natural killer cells, e.g., placenta-derived intermediate natural killer cells, with an immunomodulatory compound or thalidomide.Type: ApplicationFiled: June 2, 2020Publication date: April 29, 2021Applicant: Celularity Inc.Inventors: Xiaokui ZHANG, LIn KANG, Mohammad A. HEIDARAN, Stephen JASKO, Andrew ZEITLIN, Ajai PAL, Robert J. HARIRI
-
Publication number: 20210032596Abstract: Provided herein are methods of producing erythrocytes from hematopoietic cells, particularly hematopoietic cells from placental perfusate in combination with hematopoietic cells from umbilical cord blood, wherein the method results in accelerated expansion and differentiation of the hematopoietic cells to more efficiently produce administrable erythrocytes. Further provided herein is a bioreactor in which hematopoietic cell expansion and differentiation takes place.Type: ApplicationFiled: March 12, 2020Publication date: February 4, 2021Applicant: Celularity, Inc.Inventors: Mohammad A. Heidaran, Xiaokui Zhang, Lin Kang, Andrew Zeitlin, Vanessa Voskinarian-Berse, Stewart Abbot
-
Publication number: 20190330592Abstract: Provided herein are methods of producing natural killer cells using a two-step expansion and differentiation method. Also provided herein are methods of suppressing tumor cell proliferation, of treating individuals having cancer or a viral infection, comprising administering the NK cells produced by the method to an individual having the cancer or viral infection.Type: ApplicationFiled: July 3, 2019Publication date: October 31, 2019Applicant: Celularity, Inc.Inventors: Robert J. HARIRI, Mohammad A. HEIDARAN, Stephen JASKO, Lin KANG, Eric LAW, Ajai PAL, Bhavani STOUT, Vanessa VOSKINARIAN-BERSE, Andrew ZEITLIN, Xiaokui ZHANG
-
Publication number: 20190321413Abstract: The present invention provides methods of treating one or more complications of premature birth suffered by premature infants, comprising administering to the premature infant umbilical cord blood stem cells and, optionally, placental stem cells. The present invention also provides methods of combining and administering, and compositions comprising, umbilical cord blood stem cells, particularly autologous cord blood cells, and placental stem cells for the treatment of premature infants.Type: ApplicationFiled: May 30, 2019Publication date: October 24, 2019Applicant: CELULARITY, INC.Inventors: Mohammad A. Heidaran, Robert J. Hariri, Kristine Erickson Johnson
-
Publication number: 20170240860Abstract: Provided herein are methods of producing erythrocytes from hematopoietic cells, particularly hematopoietic cells from placental perfusate in combination with hematopoietic cells from umbilical cord blood, wherein the method results in accelerated expansion and differentiation of the hematopoietic cells to more efficiently produce administrable erythrocytes. Further provided herein is a bioreactor in which hematopoietic cell expansion and differentiation takes place.Type: ApplicationFiled: October 28, 2015Publication date: August 24, 2017Applicant: Anthrogenesis CorporationInventors: Mohammad A. Heidaran, Xiaokui Zhang, Lin Kang, Andrew Zeitlin, Vanessa Voskinarian-Berse, Stewart Abbot
-
Publication number: 20170002322Abstract: Provided herein are methods of producing natural killer cells using a two-step expansion and differentiation method. Also provided herein are methods of suppressing tumor cell proliferation, of treating individuals having cancer or a viral infection, comprising administering the NK cells produced by the method to an individual having the cancer or viral infection.Type: ApplicationFiled: September 12, 2016Publication date: January 5, 2017Applicant: Anthrogenesis CorporationInventors: Robert J. HARIRI, Mohammad A. HEIDARAN, Stephen JASKO, Lin KANG, Eric LAW, Ajai PAL, Bhavani STOUT, Vanessa VOSKINARIAN-BERSE, Andrew ZEITLIN, Xiaokui ZHANG
-
Patent number: 9464274Abstract: Provided herein are methods of producing natural killer cells using a two-step expansion and differentiation method. Also provided herein are methods of suppressing tumor cell proliferation, of treating individuals having cancer or a viral infection, comprising administering the NK cells produced by the method to an individual having the cancer or viral infection.Type: GrantFiled: November 18, 2014Date of Patent: October 11, 2016Assignee: Anthrogenesis CorporationInventors: Robert J. Hariri, Mohammad A. Heidaran, Stephen Jasko, Lin Kang, Eric Law, Ajai Pal, Bhavani Stout, Vanessa Voskinarian-Berse, Andrew Zeitlin, Xiaokui Zhang
-
Publication number: 20160287635Abstract: Provided herein are placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof. Also provided herein are compositions comprising the same, and methods of using placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof, to suppress the growth or proliferation of tumor cells, cancer cells, and the like, and to treat individuals having tumor cells.Type: ApplicationFiled: November 16, 2015Publication date: October 6, 2016Applicant: ANTHROGENESIS CORPORATIONInventors: Robert J. Hariri, Mohammad A. Heidaran, Lin Kang, Neerav Dilip Padliya, Ajai Pal, Vanessa Voskinarian-Berse, Andrew Zeitlin, Xiaokui Zhang
-
Publication number: 20160151425Abstract: Provided herein are osteogenic placental adherent cells (OPACs), methods of using OPACs and OPAC populations, and methods of culturing, proliferating, expanding, or differentiating the OPACs. Further provided herein are methods of using the OPACs to formulate implantable or injectable compositions suitable for administration to a subject. Still further provided herein are provides methods for treating bone defects with OPACs and compositions comprising OPACs. Also provided herein are methods of using OPACs in the treatment and management of multiple myeloma, e.g., reducing the progression of, halting the progression of, or improving, one or more symptoms of multiple myeloma in an individual having multiple myeloma, comprising administering a plurality of OPACs to the individual.Type: ApplicationFiled: February 2, 2016Publication date: June 2, 2016Applicant: ANTHROGENESIS CORPORATIONInventors: Sascha D. Abramson, Marian Guelakis, Mohammad A. Heidaran, Kristen Labazzo, Shmuel Yaccoby
-
Patent number: 9216200Abstract: Provided herein are placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof. Also provided herein are compositions comprising the same, and methods of using placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof, to suppress the growth or proliferation of tumor cells, cancer cells, and the like, and to treat individuals having tumor cells.Type: GrantFiled: August 13, 2012Date of Patent: December 22, 2015Assignee: Anthrogenesis CorporationInventors: Robert J. Hariri, Mohammad A. Heidaran, Lin Kang, Neerav Dilip Padliya, Ajai Pal, Vanessa Voskinarian-Berse, Andrew Zeitlin, Xiaokui Zhang
-
Patent number: 9200253Abstract: Provided herein are methods of producing erythrocytes from hematopoietic cells, particularly hematopoietic cells from placental perfusate in combination with hematopoietic cells from umbilical cord blood, wherein the method results in accelerated expansion and differentiation of the hematopoietic cells to more efficiently produce administrable erythrocytes. Further provided herein is a bioreactor in which hematopoietic cell expansion and differentiation takes place.Type: GrantFiled: August 6, 2008Date of Patent: December 1, 2015Assignee: Anthrogenesis CorporationInventors: Mohammad A. Heidaran, Xiaokui Zhang, Lin Kang, Andrew Zeitlin, Vanessa R. Voskinarian-Berse, Stewart Ernest Abbott
-
Publication number: 20150072425Abstract: Provided herein are methods of producing natural killer cells using a two-step expansion and differentiation method. Also provided herein are methods of suppressing tumor cell proliferation, of treating individuals having cancer or a viral infection, comprising administering the NK cells produced by the method to an individual having the cancer or viral infection.Type: ApplicationFiled: November 18, 2014Publication date: March 12, 2015Applicant: ANTHROGENESIS CORPORATIONInventors: Robert J. HARIRI, Mohammad A. HEIDARAN, Stephen JASKO, Lin KANG, Eric LAW, Ajai PAL, Bhavani STOUT, Vanessa VOSKINARIAN-BERSE, Andrew ZEITLIN, Xiaokui ZHANG
-
Patent number: 8926964Abstract: Provided herein are methods of producing natural killer cells using a two-step expansion and differentiation method. Also provided herein are methods of suppressing tumor cell proliferation, of treating individuals having cancer or a viral infection, comprising administering the NK cells produced by the method to an individual having the cancer or viral infection.Type: GrantFiled: July 13, 2011Date of Patent: January 6, 2015Assignee: Anthrogenesis CorporationInventors: Robert J. Hariri, Mohammad A. Heidaran, Stephen Jasko, Lin Kang, Eric Law, Ajai Pal, Bhavani Stout, Vanessa Voskinarian-Berse, Andrew Zeitlin, Xiaokui Zhang
-
Publication number: 20140322177Abstract: Provided herein are osteogenic placental adherent cells (OPACs), methods of using OPACs and OPAC populations, and methods of culturing, proliferating, expanding, or differentiating the OPACs. Further provided herein are methods of using the OPACs to formulate implantable or injectable compositions suitable for administration to a subject. Still further provided herein are provides methods for treating bone defects with OPACs and compositions comprising OPACs. Also provided herein are methods of using OPACs in the treatment and management of multiple myeloma, e.g., reducing the progression of, halting the progression of, or improving, one or more symptoms of multiple myeloma in an individual having multiple myeloma, comprising administering a plurality of OPACs to the individual.Type: ApplicationFiled: March 18, 2014Publication date: October 30, 2014Applicant: ANTHROGENESIS CORPORATIONInventors: Sascha D. Abramson, Marian Guelakis, Mohammad A. Heidaran, Kristen Labazzo, Shmuel Yaccoby
-
Patent number: 8728805Abstract: Provided herein are osteogenic placental adherent cells (OPACs), methods of using OPACs and OPAC populations, and methods of culturing, proliferating, expanding, or differentiating the OPACs. Further provided herein are methods of using the OPACs to formulate implantable or injectable compositions suitable for administration to a subject. Still further provided herein are methods for treating bone defects with OPACs and compositions comprising OPACs. Also provided herein are methods of using OPACs in the treatment and management of multiple myeloma, e.g., reducing the progression of, halting the progression of, or improving, one or more symptoms of multiple myeloma in an individual having multiple myeloma, comprising administering a plurality of OPACs to the individual.Type: GrantFiled: August 24, 2009Date of Patent: May 20, 2014Assignee: Anthrogenesis CorporationInventors: Sascha D. Abramson, Marian Guelakis, Mohammad A. Heidaran, Kristen Labazzo, Shmuel Yaccoby
-
Publication number: 20140093488Abstract: Provided herein are placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof. Also provided herein are compositions comprising the same, and methods of using placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof, to suppress the growth or proliferation of tumor cells, cancer cells, and the like, and to treat individuals having tumor cells.Type: ApplicationFiled: August 13, 2012Publication date: April 3, 2014Applicant: ANTHROGENESIS CORPORATIONInventors: Robert J. Hariri, Mohammad A. Heidaran, Lin Kang, Neerav Dilip Padliya, Ajai Pal, Vanessa Voskinarian-Berse, Andrew Zeitlin, Xiaokui Zhang
-
Patent number: 8638256Abstract: The present disclosure relates to a method for determining the position of a WLAN positioning system (WPS) and satellite positioning system (SPS) enabled device. The method can include determining an initial WPS position of the device using WPS, calculating an error region around the initial WPS position of the device, dividing the error region into a plurality of points, obtaining satellite measurements from at least two satellites in view of the device, determining a variation in a receiver clock bias for each point within the error region based on the satellite measurements from at least two satellites, selecting the point with the lowest variation in the receiver clock bias, and determining whether or not to use the point with the lowest variation in receiver clock bias to refine the initial WPS position of the device.Type: GrantFiled: September 29, 2009Date of Patent: January 28, 2014Assignee: Skyhook Wireless, Inc.Inventors: Farshid Alizadeh-Shabdiz, Mohammad A. Heidaran